News

Theresa Lynne Harrington Stukus, ANPBC NP, discusses patient compliance, side effect management, and screening anxiety in breast cancer care.

A new study reveals global gaps in integrative oncology knowledge, highlighting communication and the role of APPs in community settings.

New Phase 3 ENDURANCE trial data shows no survival benefit for indefinite lenalidomide maintenance over 2 years in non-transplant myeloma patients.

FDA approves Tudriqev with nivolumab for advanced cutaneous melanoma. Learn about dosing, safety warnings, and trial data for oncology nurses.

Explore how brain cancer-related fatigue impacts patient identity and learn practical person-centered care strategies for nurses and doctors.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses managing the influx of new breast cancer therapies and the importance of professional networking.

New research shows high-dose oral vitamin D provides rapid relief for chemo-induced erythema and radiation dermatitis without toxicity.

Oncology nurses must differentiate cyclospora from treatment side effects and use PCR-based GI panels to ensure rapid diagnosis during the outbreak.

Oncology nurse Pattie Jakel shares her story of ILC recurrence, highlighting why MRI and specialized education are vital for lobular breast cancer.

Laura Cullen DNP, RN, FAAN discusses leadership and systems infrastructure ahead of her keynote at the Roswell Park Evidence-Based Practice Symposium.

Michelle Mollica, PhD, RN, discusses training oncology nurses to manage information overload and guide patients post-diagnosis.

FDA approves Pluvicto with ARPI for PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer based on rPFS data.

Handa Oncology received FDA tentative approval for Omcazio capsules, a novel cabozantinib formulation with improved absorption and no food effects.

Learn how supportive culture and connection can improve oncology nurse retention and address burnout, shifting focus from individual responsibility.

Fumiko Chino, MD, discusses strategies for oncology nurses to address unproven treatments like ivermectin while maintaining patient trust.

Learn how healthcare teams can support young adults with cancer as they navigate dating, disclosure, body image, and setting boundaries.

Sunny Pharmtech recalls three lots of Cyclophosphamide for Injection after steel particulates were found, posing risks of thromboembolic events.

A nurse shares her story of balancing 12-hour shifts, pregnancy, and a life-changing lymphoma diagnosis in this From the Floor installment.

Oncology dietitian Gabrielle Raucci explores the role of creatine in cancer care, highlighting when to use it and risks during active treatment.

The FDA has approved perioperative pembrolizumab and enfortumab vedotin for adult patients with muscle-invasive bladder cancer.

As ivermectin interest surges via social media, oncology nurses must balance empathetic communication with evidence-based safety and clinical caution.

A study reveals only 18.3% of young adults with advanced cancer receive palliative care, highlighting a critical gap for oncology nurses to address.

New research identifies treatment initiation thresholds that impact 3-year metastasis risk in colorectal cancer patients across distinct pathways.

In the phase 3 RASolute 302 trial, oral KRAS inhibitor daraxonrasib nearly doubled median overall survival to 13.2 months in pancreatic cancer.

Oncology nurses discuss managing lung cancer as a chronic disease, addressing long-term symptoms, financial toxicity, and psychosocial care.

The FDA approved zidesamtinib for metastatic ROS1-positive NSCLC following prior kinase inhibitor therapy, offering hope for patients with resistance.

A Neurology study reveals breast cancer survivors have a high ischemic stroke risk within one year of diagnosis, linked to specific treatment regimens.

Stephanie Desrosiers discusses strategies for oncology nurses to manage chemotherapy shortages, ensuring patient safety, equity, and mental health.